![]() ![]() ![]() 0.456 P=0.0259), which might have resulted from increased tumor mutational burden (TMB) and/or microsatellite instability (MSI) relating to smoking exposure.Ĭonclusions: These findings suggest that CT scan-based evaluation is not able to accurately reflect the pathological response to immunotherapy and that smoking signature is a superior marker to PD-L1 expression in predicting the benefit of immunotherapy in NSCLC patients. Importantly, we found that the smoking signature displayed a better performance than programmed death-ligand 1 (PD-L1) expression in predicting the pathological response (area under the curve: 0.690 vs. After neoadjuvant treatment, computed tomography (CT) scan-based evaluation showed poor agreement with the postoperatively pathological examination (weighted kappa =0.0225 P=0.795), suggesting the poor performance of CT scans in evaluating the response to immunotherapy. The most common histological subtype was lung squamous cell carcinoma (LUSC) (n=28, 71.8%), followed by lung adenocarcinoma (LUAD) (n=11, 28.2%). Results: A total of 39 patients (35 males and 4 females) were included. Clinicopathological factors associated with pathological response were analyzed. Methods: We retrospectively collected the clinicopathological characteristics and treatment outcomes of non-small cell lung cancer (NSCLC) patients who received neoadjuvant immunotherapy or chemo-immunotherapy followed by surgery between 20 at a large academic thoracic cancer center. Neoadjuvant immunotherapy provides an ideal setting for exploring responsive biomarkers because the pathological responses can be directly and accurately evaluated. ![]() #These authors contributed equally to this work.īackground: There is a paucity of biomarkers that can predict the degree of pathological response to immunotherapy. Schmid 6, Ren-Wang Peng 6, Toyoaki Hida 7, Zhexin Wang 1, Feng Yao 1ġ Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China Ģ Clinical Research Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China ģ Institute for Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China Ĥ Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA ĥ Department of General and Special Surgery, Faculty of Medicine, The Hashemite University, Zarqa, Jordan Ħ Division of General Thoracic Surgery, Department of BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland ħ Lung Cancer Center, Central Japan International Medical Center, Minokamo, Gifu, JapanĬontributions: (I) Conception and design: H Yang, W Ma, F Yao (II) Administrative support: Z Wang, F Yao (III) Provision of study materials or patients: B Sun, L Fan, K Xu (IV) Collection and assembly of data: B Sun, L Fan, K Xu (V) Data analysis and interpretation: W Ma, B Sun, L Fan, K Xu (VI) Manuscript writing: All authors (VII) Final approval of manuscript: All authors. ![]() Hall 4, Mohammad Faisal Al-Hurani 5, Ralph A. Haitang Yang 1#^, Wenyan Ma 2#, Beibei Sun 3#, Liwen Fan 1, Ke Xu 1, Sean R. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |